Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated July 16, 2024, serves as a transaction notification for the month of July 2024. The document discloses share transactions executed by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions primarily involve the re-investment of dividends paid on July 11, 2024, into the Company's Deferred Annual Bonus Plan, Performance Share Plan, and Individual Savings Accounts (ISAs).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics for GSK plc. It exclusively reports on specific share acquisition volumes and prices for individual executives.
| Instrument | Transaction Date | Price | Exchange |
|---|---|---|---|
| Ordinary Shares (GBP) | July 15, 2024 | £15.0500 | London Stock Exchange (XLON) |
| Ordinary Shares (GBP) | July 12, 2024 | £15.2522 | London Stock Exchange (XLON) |
| American Depositary Shares (USD) | July 15, 2024 | $38.9000 | New York Stock Exchange (XNYS) |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. The only changes disclosed are increases in the notional interest or acquisition of shares by specific executives as part of standard compensation plan mechanics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a routine regulatory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16.
Important Facts for Investors
- Transaction Nature: All reported transactions are acquisitions or increases in notional interest resulting from dividend re-investment, not open-market purchases or sales by executives.
- Dividend Date: The underlying dividends were paid to shareholders on July 11, 2024.
- Key Executives Involved: Transactions were reported for CEO Emma Walmsley, CFO Julie Brown, Non-Executive Director Dr. Hal Barron, and several other senior officers including the Chief Scientific Officer and Chief Commercial Officer.
- Share Price: Ordinary shares traded at £15.0500 on July 15 and £15.2522 on July 12; ADSs traded at $38.9000 on July 15.
- Plan Types: Transactions occurred within the Deferred Annual Bonus Plan, Performance Share Plan (subject to a 2-year holding period), and ISAs.